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ABSTRACT
Background and Objective Air temperature changes
are associated with increased cardiovascular and
respiratory risk, but the roles of inflammatory and
coagulation markers are not well understood. We
investigated the associations between temperature and
several blood markers in patients with coronary heart
disease (CHD) and pulmonary disease (PD).
Methods Two studies were conducted in Erfurt,
Germany, over two successive winters. 578 and 381
repeated blood measurements were collected from 57
CHD and 38 PD patients, respectively. Data on patient
characteristics and disease history were gathered at
baseline. Meteorological data were collected from
existing networks. Associations were analysed using
additive mixed models with random patient effects. Effect
modification by diabetes status was investigated only in
CHD patients, as only two PD patients had diabetes.
Results Mean daily air temperature varied between
138C and 168C in both study periods. A 108C decrease
in the 5-day temperature average before blood
withdrawal led to an increase in platelet counts (%
change from the mean: 3.0%, 95% CI 0.6% to 5.5%) and
fibrinogen (5.5%, 1.3% to 9.7%), no change in C-reactive
protein in PD patients, and a decrease in C-reactive
protein in CHD patients. A 2-day delayed increase in
factor VII associated with temperature decrease was
seen in CHD patients (4.9%; 0.7% to 9.2%), while PD
patients showed no effect. ‘Effects in CHD patients
without diabetes’ into ‘Effects on factor VII in CHD
patients without diabetes’.
Conclusions This study suggests that temperature
decrease is associated with change in several blood
parameters. The complex interplay of blood markers at
low temperature may contribute to the observed
association between cold and cardiovascular mortality
and morbidity.
INTRODUCTION
Several studies have shown that changes in air
temperature are associated with hospital admis-
sions1 2 and mortality3e5 due to cardiovascular
events. Elderly people and those with diabetes or
chronic obstructive pulmonary disease (COPD)
seem to be susceptible to extreme weather
conditions.6e8However, theunderlyingmechanisms
of the relationship between temperature and
cardiovascular morbidity remain poorly understood.
Earlier studies on the controlled exposure of
participants to cold air or water revealed an increase
in the levels of red blood cells (RBC), platelets,
factor VII (FVII) and fibrinogen and a decline in von
Willebrand factor (vWf).9e11 A Taiwanese study12
found higher mean fibrinogen and FVII concentra-
tions on days with an ambient temperature equal
to or below 208C compared to days with an
ambient temperature above 208C. Seasonal varia-
tions in C-reactive protein (CRP) levels were
observed in healthy Koreans with higher values
during winter and spring than in summer.13 The
association between temperature and repeated
fibrinogen, CRP and interleukin-6 (IL-6) measure-
ments was assessed in a multi-centre European
study of survivors of myocardial infarction.14 A
decrease in temperature 3 days before the measure-
ment was associated with an increase in fibrin-
ogen, CRP and IL-6 levels seemed to be related to
average temperature changes in the previous 5
days.
It is hypothesised that a wide range of blood
markers are involved in the development of
atherosclerosis leading to chronic as well as acute
cardiovascular disease. In patients with coronary
or pulmonary disease, increased levels of inflam-
matory or coagulation markers might predict
future cardiovascular events.15 16 Therefore,
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elevated blood markers due to decreased temperature might
indicate cardiovascular health. The objective of our study was to
assess the influence of temperature on repeated measurements of
cellular blood components, adhesion molecules and coagulation
as well as inflammatory markers as indicators for cardiovascular
health in susceptible subgroups. We investigated the direction
and temporal delay of the temperatureeblood marker response
and whether this differs in subjects with pulmonary and
cardiovascular disease. Our hypothesis was that there would be
a similar response to temperature stimuli in both groups.
Abnormalities in the haemostatic system and low-grade
systemic inflammation were found in people with diabetes.17 18
Nakaji et al19 observed an increase in diabetes-related mortality
during the winter season in Japan; thus, we were also interested
in the possible effect modifications of diabetes status on the
relationship between temperature and blood markers.
METHODS
Study populations
As part of the University of Rochester Particulate Matter Center
investigations, two prospective panel studies were conducted in
Erfurt, Germany. The first study was carried out between 15
October 2000 and 27 April 2001 with a group consisting of
non-smoking men with coronary heart disease (CHD). Male
participants with a history of doctor-diagnosed impaired lung
function and/or chronic pulmonary disease took part in the
second study between 15 October 2001 and 6 May 2002.
All participants signed a written consent form and the study
protocol was approved by the Ethics Commission of the Bavarian
Chamber of Physicians (‘Bayerische Landesaerztekammer ’).
Patients taking anti-coagulants (except for acetylsalicylic acid)
and those with an implanted cardiac pacemaker, a recent (<3
months previously) myocardial infarction, bypass surgery,
coronary angioplasty or diabetes mellitus type I were excluded
from both groups. Additionally, participants in the pulmonary
disease (PD) group with pneumoconiosis (silicosis or asbes-
tosis), more than three hospitalisations for COPD in the
previous year, or continuing oxygen therapy and those who
had taken antibiotics more than four times during preceding
6 months or winter half-year were excluded.
Clinical measurements
For each participant up to 12 clinical examinations were
scheduled every two weeks on the same week day and at the
same time of day. At the first visit, a baseline questionnaire was
administered regarding health status, pulmonary and cardiac
symptoms, medication and smoking history. Each visit included
a short interview and ethylenediaminetetraacetic acid (EDTA)
and citrate plasma samples were drawn (Becton Dickinson,
Franklin Lakes, NJ). Samples were centrifuged and aliquots were
immediately stored at 208C until analysis. All blood specimens
were analysed using an Abbott Cell-Dyn 1800 cell counter
(Abbott, Wiesbaden, Germany). Intercellular adhesion molecule
1 (ICAM-1), endothelial-leukocyte adhesion molecule (E-
selectin) (R&D Systems, Wiesbaden, Germany), prothrombin
fragment 1+2 (Dade Behring, Marburg, Germany) and soluble
CD40 ligand (sCD40L) were measured by means of a commer-
cial enzyme-linked immunosorbent assay (ELISA). sCD40L
measurements were only available for the CHD group. D-dimer
and vWf were analysed using an immunoturbidimetric method
and FVII by clotting time (Diagnostica Stago, Asnieres-sur-Seine,
France). Fibrinogen, CRP (high-sensitivity assay) and serum
amyloid A (SAA) were analysed by immunonephelometry (Dade
Behring).
Meteorological data
Hourly data on temperature, relative humidity and barometric
pressure were collected from existing networks. For each person
and visit, the individual 24 h average of each meteorological
variable preceding the visit (0e23 h before blood withdrawal) for
up to 4 days (24e47 h, 48e71 h, 72e95 h, 96e119 h) before the
examination were calculated if more than two thirds of the
hourly measurements were available for this period. Addition-
ally, we calculated the mean of these 5 days (5-day average).
Statistical analysis
Analyses were performed with SAS (v 9.1) in both groups
separately. The medians of patient-specific correlation coeffi-
cients between all blood markers were calculated. In order to
compare the blood parameters between the groups, the two
datasets were combined and mixed models with random patient
effects were conducted including a dummy variable for the
group effect. We assumed a compound symmetry structure for
the covariance matrix, as the half-lives of the markers were
much shorter than the intervals between the visits. To compare
the meteorological variables between the groups, a regression
model with a first-order autoregressive covariance structure was
used to account for the dependencies between the repeated
measurements. The p value of the group effect indicates
whether the blood markers and meteorological variables differ
significantly between the groups. The patient characteristics of
both groups were compared using a t test for metric variables
and a c2 test for categorical variables. In case of less than five
observations in one category, Fisher ’s exact test was used.
Regarding the estimation of temperature effects, the data of
each group were analysed separately using additive mixed
models with random patient effects and a compound symmetry
covariance structure. In both groups, prothrombin fragment 1
+2, CRP, SAA and D-dimer and, only in the CHD group,
sCD40L and FVII were log-transformed in order to produce
normally distributed residuals. Penalised splines (P-splines) were
used to allow for non-linear exposureeresponse functions and
for non-linear confounder adjustment (S Greven, H Küchenhoff,
A Peters, personal communication, 2008).
Confounder models were built separately for each blood
parameter. Model selection was carried out by minimising
Akaike’s information criterion. Continuous confounders were
included linearly or smoothly as P-splines depending on the
Akaike’s information criterion value. Long-term time trend and
relative humidity with the same lag as the temperature term
were forced into the model. Barometric pressure with the same
lag as the analysed temperature lag and day of the week were
only included in case of model fit improvement. Two variables
with questionnaire information indicating an airway infection
or antibiotic intake 2 weeks before blood withdrawal were
forced into the model to account for possible inflammation
unrelated to a change in temperature. In addition, for the PD
group, a variable for corticosteroid intake was also taken into
account. Observations with obviously large residuals in the
confounder model were excluded.
After completion of the confounder models, the effects of
temperature lags were estimated linearly as well as smoothly as
P-splines. The linearly estimated temperature effects are
presented as per cent change in the outcome mean per 108C
decrease in temperature together with 95% CIs. We chose to
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present the effects of a decrease in temperature because both
groups were mainly studied in the winter.
Effect modification
We considered body mass index (BMI) (#30 kg/m2 vs >30 kg/
m2), hypertension (yes vs no), age (#60 years vs >60 years) and
statins (intake vs no intake) as potential effect modifiers. The
interaction with diabetes type II (yes vs no) was only analysed
for the CHD group as only two patients in the PD group had
diabetes. Additionally, interactions with smoking status (current
smokers vs non-smokers) and b2-agonists (intake vs no intake)
were analysed for PD patients.
Sensitivity analyses
To check the robustness of our models we performed several
sensitivity analyses. Temperature effects were calculated
including observations with extremes in the residuals to avoid
exclusion of observations possibly sensitive to temperature
changes and to test the sensitivity of the results to our main
model. Also, patients with pulmonary disease (COPD, chronic
bronchitis) were excluded from the CHD group, and patients
with coronary disease (CHD, angina pectoris and previous
myocardial infarction) from the PD group. Additionally, we
separately added particulate matter with a diameter below
10 mm (PM10) or ultrafine particles (UFP) with the same lag as
temperature, as well as with the most influential lag, to the
original confounder model. Polynomial distributed lag (PDL)
models were calculated, which include all temperature lags
simultaneously. In order to avoid multicollinearity, we used an
Almon distributed lag model,20 which forces estimates to
a polynomial shape. The sum of the lagged temperature effects
resulting from a PDL model were compared with the effect of
the 5-day temperature average.
RESULTS
Study populations
Of the initial 61 CHD patients, one refused to participate, two
were excluded due to disease causing changes in blood markers
(leukaemia, lymphoma) and one was excluded because of
constantly elevated levels of leukocytes and erythrocytes, indi-
cating an unknown underlying disease. The CHD group there-
fore comprised 57 men. Fifty five patients participated in 12
scheduled visits, while two attended nine and eight examina-
tions, respectively. If patients reported an acute infection and/or
surgery during the 2 weeks before the examination or if nurses
saw signs of acute infection, the blood samples of the respective
visits were excluded (46 blood samples from 19 patients). As not
all patients were able to give the scheduled amount of blood at
each visit, 578 (85%) blood samples remained for analysis.
The data of 38 of 42 male PD participants were used for
analyses: three participants with a single measurement and one
patient with a cancer diagnosis were excluded. In total, 438
(96%) of the targeted 456 visits were carried out. Blood with-
drawal failed for technical reasons on 10 occasions and 47 blood
samples were excluded because of fever the week before with-
drawal or a diagnosed airway infection on the day of the visit.
Thus, 381 (87% of 438 blood withdrawals) valid blood samples
were available for analysis. The majority of patients had chronic
bronchitis and/or asthma with normal pulmonary function tests
measured as forced expiratory volume in 1 s (FEV1)/forced vital
capacity ratios above 70%. Two patients had mild, seven
moderate (50%£FEV1/FEV1predicted <80%) and five severe (30%£
FEV1/FEV1predicted <50%) COPD.
The PD and CHD groups are described in table 1. CHD
patients were significantly older than PD patients: the age of
CHD and PD patients ranged from 51 to 76 years and from 35
and 78 years, respectively. Significantly more patients with
chronic bronchitis were observed among CHD patients with
diabetes than without diabetes. Overall, the PD group was
healthier as the participants tended to be less obese and it
included only two patients with diabetes, while the CHD group
included 13 patients with diabetes.
Clinical measurements
Levels of blood parameters are summarised in table 2. Except for
E-selectin, vWf, D-dimer and SAA, PD patients tended to have
higher values than CHD patients. Only platelets, prothrombin
fragment 1+2 and ICAM-1 showed significant differences
between the groups. CHD patients with diabetes had higher E-
selectin and ICAM-1 levels compared to CHD patients without
diabetes. CRP and SAA showed a moderate correlation of r¼0.7
(CHD) and r¼0.6 (PD) in both groups. None of the remaining
blood markers were strongly correlated (|r|<0.4) in either
group.
Meteorological data
Meteorological data were measured on 198 and 204 days for the
CHDand PDgroups, respectively (see online supplemental table 1).
The mean temperature during both study periods was 48C (SD
58C). Mean relative humidity was 84% (SD 9%) and 83% (SD
12%) and mean barometric pressure was 973 hPa (SD 10 hPa)
and 980 hPa (SD 11 hPa) for the CHD and PD groups, respec-
tively. Only barometric pressure showed a significant difference
between the groups. The meteorological variables exhibited only
low correlation (|r|#0.3). Online figure 1 compares the time
series of temperature in both groups.
Effects of air temperature
There was no evidence in either group for a deviation in the
linearity of the relationship between temperature and blood
markers (data not shown). Figures 1 and 2 show the immediate,
lagged and cumulative effects of a 108C decrease in temperature.
All figures are presented with the same scaling except for RBC
which exhibits very small temperature effects. The association
between temperature and RBC was quite similar for both
groups, but with an immediate significant effect in CHD
patients (0.7%, 0.0% to 1.4%). In contrast, CHD patients reacted
to a drop in temperature, particularly the 5-day average, with
decreased (3.6%, 6.9 to 0.4%) platelet levels, whereas PD
patients responded with increased (3.0%, 0.6% to 5.5%) platelet
levels. A decline in temperature was associated with an increase
in sCD40L in CHD patients, with the 5-day temperature average
showing the largest effect (18.5%, 5.1% to 33.5%). Only in PD
patients was a decline in all temperature lags associated with
increased E-selectin levels. A drop in temperature for the 5-day
average led to a 4.6% (0.2% to 9.1%) increase in ICAM-1 in CHD
patients. A 6.5% (12.7% to 0.2%) reduction in vWf
24e47 h before blood withdrawal was detected in PD patients.
We observed large differences between the groups for the rela-
tionship between temperature and FVII. While PD patients
showed an immediate decrease in FVII (5.6%, 10.4 to
0.7%), CHD patients exhibited an inverse association of
roughly the same size with a delay of 2 days (4.9%, 0.7% to
9.2%). We found only in PD patients an association between
temperature and prothrombin fragment 1+2 with a delay of
1e3 days with the largest effect for the 5-day average (25.9%,
7.6% to 47.3%). No clear effects were detected for fibrinogen. A
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decrease in temperature 96e119 h before blood withdrawal and
in the 5-day average led to a borderline significant reduction of
about 5% in CHD patients, whereas PD patients showed
elevated fibrinogen levels for a temperature decrease 24e47 h
(5.0%, 1.2% to 8.7%), 48e71 h (5.2%, 2.0% to 8.4%) and
72e95 h (3.4%, 0.5% to 6.4%) before blood withdrawal and for
the 5-day temperature average (5.5%, 1.3% to 9.7%). We
detected only in CHD patients influential associations between
a temperature decrease and CRP. Nearly all temperature lags
showed a statistically significant or borderline decrease in CRP,
with the largest influence for the 5-day temperature average
(16.1%, 26.8% to 3.8%). In both groups we found no
influence of temperature on WBC, D-dimer or SAA (data not
shown).
Effect modification
Only CHD patients with diabetes exhibited a decrease in
platelets in association with a decline in temperature (figure 3).
Participants with and without diabetes showed elevated and
decreased levels of E-selectin and vWf, respectively, due to
a decrease in temperature, which were not significant. We
observed the largest interaction effects between temperature and
diabetes on FVII. Patients with diabetes showed strongly
elevated FVII values for a decrease in temperature for almost all
lags, while there were no effects for patients without diabetes.
No significant interactions by diabetes were detected in associ-
ation with the remaining blood markers.
Temperature effects on platelets were more pronounced in
CHD patients without statin intake, whereas CHD patients
taking statins showed larger effects on E-selectin (data not
shown). In PD patients we observed only temperature effects
on prothrombin fragment 1+2 in patients with statin intake.
Throughout all 24 h lags, these participants exhibited signifi-
cantly elevated levels due to a drop in temperature, whereas the
effect of patients who did not take statins was smaller and
mostly not significant. In both groups, no significant interac-
tions of temperature with age, BMI or hypertension were
detected. Smoking status and intake of b2-agonists did not
modify the temperatureeblood marker response in PD
patients.
Sensitivity analyses
In both groups the temperature effects remained robust after
adjustment for air pollution. Only in CHD patients were
temperature effects on RBC, ICAM-1 and vWf more pronounced
after adjusting for PM10 with the same lag as temperature. The
exclusion of PD patients from the CHD group and of patients
with coronary disease from the PD group did not change our
Table 1 Baseline characteristics of the PD and CHD groups
CHD group (n[57) PD group (n[38)
All mean (SD)
or n(%)
No diabetes
mean (SD) or n(%) Diabetes, N (%)
p Value (no diabetes
vs diabetes) mean (SD) or n(%)
p Value
(PD vs CHD)
Age (years), mean (SD) 66.3 (6.0) 66.0 (6.2) 67.3 (5.7) 0.50* 53.8 (12.3) <0.001*
BMIz (kg/m2), mean (SD) 28.1 (3.4) 28.2 (3.4) 27.6 (3.5) 0.57* 25.5 (3.7) 0.06*
Age (years)
#60 8 (14) 7 (16) 1 (8) 0.67z 17 (45) <0.001y
>60 49 (86) 37 (84) 12 (92) 21 (55)
BMI (kg/m2)
#30 42 (74) 31 (70) 11 (85) 0.48z 33 (87) 0.12y
>30 15 (26) 13 (30) 2 (15) 5 (13)
Smoking
Never smoker 15 (26) 14 (32) 1 (8) 0.15z 8 (21) 0.003z
Ex-smoker 42 (74) 30 (68) 12 (92) 23 (61)
Current smoker 0 (0) 0 (0) 0 (0) 7 (18)
History of
Coronary heart disease 57 (100) 44 (100) 13 (100) e 11 (29) <0.001z
Angina pectoris 39 (68) 29 (67) 10 (77) 0.73z 15 (40) 0.004y
Myocardial infarction 43 (57) 33 (75) 10 (77) 0.89y 8 (21) <0.001y
Bypass surgery/balloon
dilatation
49 (68) 37 (84) 12 (92) 0.67z 4 (11) <0.001z
COPDx (mild to severe) 5 (9) 5 (11) 0 (0) 0.58z 14 (37) <0.001y
Chronic bronchitis 2 (4) 0 (0) 2 (15) 0.05z 29 (76) <0.001z
Emphysema 0 (0) 0 (0) 0 (0) e 5 (13) 0.009yy
Bronchial asthma 0 (0) 0 (0) 0 (0) e 20 (53) <0.001yy
Hypertension 40 (70) 32 (73) 8 (62) 0.44y 14 (37) 0.001y
Diabetes 13 (23) 0 (0) 13 (100) e 2 (5) 0.02z
Medication use
Acetylsalicylic acid 53 (93) 42 (96) 11 (85) 0.22z 11 (29) <0.001z
Statins 28 (49) 22 (50) 6 (46) 0.81y 7 (18) 0.002y
b2-Agonists 4 (7) 3 (7) 1 (8) 1.00y 21 (56) <0.001z
Theophylline 6 (11) 5 (11) 1 (8) 1.00y 17 (45) <0.001y
Glucocorticosteroids 4 (7) 3 (7) 1 (8) 1.00y 18 (47) <0.001z
*t test;
yc2 test;
zFisher’s exact test.
BMI, body mass index; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; PD, pulmonary disease.
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findings. The sums of the lagged temperature effects resulting
from PDL analyses were comparable to the effects of 5-day
temperature average on all blood markers in both groups (data
not shown).
DISCUSSION
Summary
We investigated the cardiovascular effects of temperature in two
susceptible subgroups. We observed opposite air temperature
effects between the groups for platelets, E-selectin, prothrombin
fragment 1+2, FVII and fibrinogen. In association with a 108C
decline in temperature, PD patients showed an increase in blood
parameters except for FVII, while CHD patients showed
constant or decreased blood marker levels. Inverse immediate
and lagged effects were found on sCD40L, which was measured
in the CHD group only. Immediate decreased FVII levels in
association with a 108C decrease in the 24 h temperature average
were detected in PD participants, whereas CHD patients
showed increased FVII levels with a delay of 48e71 h. Patients
with CHD and diabetes showed in particular a strong associa-
tion between temperature and platelets as well as FVII, whereas
no or opposite effects were observed in both PD and CHD
participants without diabetes, respectively. The results indicate
that decreases in temperature might lead to changes in coagu-
lation markers and adhesion molecules, suggesting a biological
mechanism for the observed temperature-related variation in
cardiovascular event frequency.
Air temperature and blood parameters
RBC tended to increase as temperature decreased. These findings
support other studies which showed elevated RBC after
cooling.9 11 Elwood et al21 found an absolute increase in platelets
of 163103/ml in association with a 168C decrease in temperature
which is comparable with the 103103/ml platelet increase in PD
patients for the same temperature decline found in our analysis.
Increased platelet counts were also observed during mild surface
cooling,11 probably as a consequence of cold-induced sympa-
thetic activity. Contrary to our findings in PD participants, we
observed a positive association in CHD patients. Considering
the significantly increased sCD40L levels in CHD participants,
the decrease in platelets could be the consequence of platelet
aggregation due to activation of platelets.22 Unfortunately, no
sCD40L data were available for the PD group to allow us further
investigate this hypothesis. De Lorenzo et al10 showed that vWf,
a glycoprotein which mediates platelet adhesion, decreased in
healthy participants due to cold adaptation following whole
body water immersion. In our results, reduced vWf levels in
association with a drop in temperature were seen in both
groups. However, the effects were mostly not significant.
FVII activates the clotting cascade and Woodhouse et al23
observed enhanced FVII clotting activity values in the elderly
during winter. However, one should only cautiously refer to
studies comparing winter-time and summer-time levels of blood
markers, as the differences may be due to differences in influenza
occurrence rather than temperature changes. Yeh et al12 found
higher mean FVII levels in Taiwanese subjects on days with
a temperature equal to or below 208C in comparison to days
exceeding 208C. Although temperature ranges between our and
the Taiwanese study differed, we also detected cold effects on
FVII in CHD patients. Opposite effects were observed in PD
participants. Several studies21 23 24 observed enhanced fibrinogen
levels in the elderly during winter. To our knowledge there was
only one study which assessed the influence of temperature on
repeated measurements of fibrinogen. Schneider et al14 observed
increased fibrinogen levels in association with a decrease in
temperature in survivors of myocardial infarction. A 108C drop
in temperature 72e95 h before blood withdrawal led to a 1.32%
(0.2% to 2.4%) increase in fibrinogen. We also found lagged
temperature effects in PD patients, but our effects were larger
and significant for several lags. However, in CHD patients
a delayed decrease in fibrinogen was found. This is in accordance
with the report by Frohlich et al25 who reported peak fibrinogen
levels in April and lower levels in winter. Fibrinogen is
a precursor of fibrin which is responsible for thrombus forma-
tion. High levels of fibrinogen are a marker of systemic inflam-
mation, while low levels can indicate systemic activation of the
clotting cascade. Schneider et al14 detected elevated values of
CRP in relation to a decline in temperature. However, we found
no effect on CRP in PD patients and a decrease in CRP for
almost all lags in CHD patients. The findings on seasonal
changes of CRP are controversial. While Sung13 reported
seasonal variation in CRP levels with a peak in winter,
Table 2 Blood marker levels for PD and CHD patients
CHD group (N[57) PD group (N[38)
All No diabetes Diabetes p Value*
(no diabetes
vs diabetes)n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
p Value (PD
vs CHD)
WBC (31000/ml) 576 6.7 (1.6) 447 6.6 (1.6) 129 7.2 (1.6) 0.15 379 7.0 (1.9) 0.36
RBC (31000/ml) 575 4.6 (0.4) 447 4.6 (0.3) 128 4.5 (0.4) 0.33 379 4.6 (0.3) 0.66
Platelets (31000/ml) 572 184.4 (64.1) 445 180.0 (43.4) 127 199.8 (108.0) 0.39 380 255.9 (62.9) <0.001
sCD40L (pg/ml) 538 5256 (4480) 423 5327 (4751) 115 4993 (3299) 0.79 e e (e) e
E-selectin (ng/ml) 571 54.1 (26.3) 446 49.4 (19.8) 125 70.7 (37.5) 0.03 376 50.0 (20.7) 0.60
ICAM-1 (ng/ml) 572 271.2 (72.1) 446 259.1 (58.1) 126 314.2 (96.7) 0.01 377 300.7 (97.6) 0.02
vWF (% activity) 544 134.3 (57.3) 423 131.4 (53.4) 121 144.6 (68.5) 0.28 349 126.4 (43.4) 0.41
FVII (% activity) 535 120.7 (33.0) 418 119.7 (33.3) 117 124.1 (31.6) 0.78 345 130.2 (32.8) 0.06
Prothrombin
fragment 1+2
(nmol/l)
541 1.5 (1.8) 423 1.5 (1.6) 118 1.7 (2.5) 0.18 345 2.2 (1.0) <0.001
Fibrinogen (g/l) 573 2.9 (0.7) 444 2.9 (0.7) 129 2.9 (0.7) 0.98 374 3.0 (0.7) 0.41
D-dimer (mg/ml) 546 0.7 (1.1) 425 0.6 (0.5) 121 1.1 (2.1) 0.22 347 0.4 (0.6) 0.14
CRP (mg/l) 575 3.4 (4.1) 446 3.1 (3.3) 129 4.6 (5.8) 0.08 379 3.5 (5.5) 0.77
SAA (mg/l) 575 5.1 (8.7) 446 4.8 (8.9) 129 6.0 (7.9) 0.23 378 4.6 (8.4) 0.64
*p Value of fixed group effect in mixed effects model.
CHD, coronary heart disease; CRP, C-reactive protein; E-selectin, endothelial-leukocyte adhesion molecule; FVII, factor VII; ICAM-1, intercellular adhesion molecule 1; PD, pulmonary disease;
RBC, red blood cell count; SAA, serum amyloid A; sCD40L, soluble CD40 ligand; vWF, von Willebrand-factor antigen; WBC, white blood cell count.
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Horan et al26 and Frohlich et al27 found no seasonal variation.
CRP is the most established inflammatory marker used to
evaluate and predict cardiovascular health.15 However, we
mainly observed changes in coagulation markers which might
also be relevant in the development of acute coronary syndromes
and in thrombus formation.28
Air temperature and blood parameters in patients with diabetes
We detected interaction effects between diabetic status and
temperature on platelets, E-selectin, vWf and FVII in CHD
patients. The inverse influence of a drop in temperature on FVII in
all CHD patients might be based on the strong inverse tempera-
ture effect in people with diabetes. CHD patients without dia-
betes showed non-significant effects comparable to the estimates
for the PD group,which included only two patientswith diabetes.
While smaller or opposite effects were detected in patients
without diabetes, a decline in temperature also led to decreased
platelets and slightly increased E-selectin and vWf levels in
patients with diabetes. The haemostatic system in individuals
with diabetes exhibits various abnormalities17 such as endothelial
Figure 1 Per cent change per 108C decrease in temperature in mean levels of red blood cells (RBC), platelets, soluble CD40 ligand (sCD40L),
E-selectin, intercellular adhesion molecule 1 (ICAM-1) and von Willebrand-factor antigen (vWF). CHD, coronary heart disease; PD, pulmonary disease.
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damage and elevated coagulation markers. The decrease in plate-
lets in association with a temperature drop might be due to
enhanced vWf levels which promote platelet adhesion to the
damaged endothelial tissue and subsequent platelet activation.29
Our analyses revealed that patients with diabetes seem to be
a susceptible subpopulation which reacted more strongly to cold
temperature. This finding needs further investigation as
Schwartz6 and Medina-Ramon and Schwartz30 observed in case-
only analyses increased hospital admissions and deaths in patients
with diabetes on extremely hot days but no effects of extreme
cold. As the study periods of our groups were limited to the cold
season we expected no heat effects.
In summary, contrary to our initial hypothesis, the relationship
between temperature and most blood markers differed between
the groups or clear temperature effects were detected only in one
group. CHD patients in our study were older and more often had
hypertension and diabetes than PD patients. Medication also
varied because of different disease patterns between the groups.
The combination of all these factors possibly affected blood
markers and susceptibility to temperature. Thus, differences in
the effect of temperature between the groups could not be fully
explained by a single patient characteristic. It is possible that
underlying, but currently unknown, mechanisms influencing the
association between temperature and blood markers might differ
between the two susceptible subgroups. However, it is also
possible that our results are only due to chance.
Air temperature and cardiovascular events
As several studies5 31 observed increases in cardiovascular events
due to a decline in temperature, our analyses might identify
intermediate steps linking temperature changes to cardiovas-
cular health. The influence of temperature on cardiovascular
eventshas alsobeendescribedbyU-,V- or J-shaped functions.2 32e34
In this context, it is important to note that the clinical examina-
tions of the CHDand PDpatients took place fromOctober toApril
or May, respectively. The maximum 24 h averages in temperature
during both studyperiods never exceeded 168C.Weassume that our
results reflect the left part of a U- or V-shaped temperatureeblood
marker response as it has been shown that cardiovascularmortality
is lowest on days with a mean temperature between 158C and
208C.34
Strengths and limitations
We were able to analyse intra-individual variation as patients
with PD or CHD participated in up to 12 consecutive blood
measurements. Further strengths are the non-linear confounder
adjustment and the information on patient characteristics
allowing us to perform subgroup analyses. However, the find-
ings are limited in that the measured blood markers are easily
influenced by infections. CRP is particularly sensitive to infec-
tious disease and can increase a thousand-fold within a short
time.35 We therefore excluded the blood samples of participants
with an acute infection during their visit and we additionally
Figure 2 Per cent change per 108C decrease in temperature in mean levels of factor VII (FVII), prothrombin fragment 1+2, fibrinogen and C-reactive
protein (CRP). CHD, coronary heart disease; PD, pulmonary disease.
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adjusted for intake of antibiotics and airway infections during
the 2 weeks prior to the examination. It can therefore be
assumed that the presented effects result from a temperature
decrease and not from an infectious disease. It has also been
shown that air pollutants might be associated with blood
markers.36e42 It is still unclear whether air pollutants confound
or modify the temperatureeblood marker response. However,
adjustment for air pollution hardly changed our results.
There is no standard technique to determine sCD40L and it
has been shown that sCD40L levels may be influenced by the
method employed. However, in our study all samples were
analysed at the same time and under the same conditions (for
further details, see Rückerl et al22). Moreover, the change in the
sCD40L level within one patient was used for analysis, rather
than the absolute level, and therefore the assay itself cannot
have influenced the results.
One limitation is that we investigated the influence of
temperature on blood parameters in men with severe disease on
different medication. Hence, they are a highly selected group
which might show differing reactions to temperature changes
compared to women or healthy subjects, leading to reduced
generalisability of our results. On the other hand, analysing
vulnerable groups might provide more mechanistic insights and
provide ideas for instituting new precautions. A further limita-
tion is that only outdoor temperature was measured although
people usually spend a lot of time indoors, especially in winter.
However, as numerous studies have shown that the risk for
cardiovascular events increases during the cold season,5 34 we
assume that short exposure to outdoor temperature can also
influence blood markers.
CONCLUSION
The present study suggests that a decrease in temperature is
associated with changes in several blood parameters. The
direction and timing of the relationship differed between CHD
and PD patients. The complex interplay of blood markers at low
temperature may contribute to the observed association
between cold and cardiovascular mortality and morbidity.
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